Immunome Inc., a biotechnology company focused on developing targeted cancer therapies, has promoted Max Rosett to Chief Financial Officer, effective May 9.   Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since January 2024.   “Max has been instrumental in Immunome’s rapid transformation over the last year, driving execution of major initiatives including our merger with Morphimmune, our strate...